Overexpression of ASPH protein predicts poor outcomes in retroperitoneal liposarcoma patients

To the Editor:Liposarcoma is a common subtype of retroperitoneal sarcoma.Due to the complicated anatomical heterogeneity of retroperitoneal liposarcoma(RPLS),it compresses and invades adjacent important organs,and massive bleeding frequently occurs during surgery.Therefore,a combined visceral resection is required,which means that RPLS surgery has greater difficulty and a lower complete resection rate compared to surgeries for other solid tumors.Although in our previous studies we found that intraperitoneal thermoperfusion chemotherapy including cisplatin may improve the prognosis of patients with RPLS,[1]surgery is the most effective treatment for RPLS,and adjuvant therapies have shown almost ineffective.There is a paucity of research focusing specifically on molecular mechanisms underlying RPLS pathogenesis.Consequently,no diagnostic biomarkers,druggable targets,or prognostic factors are available for RPLS.